Glucosamine & Chondroitin

AOR04308

Shellfish-free formula

  • Two key joint health compounds in one formula
  • Relieves joint pain from arthritis
  • Provides clinically proven doses
Gluten Free
Non-GMO

$43.69 or subscribe and save 20%

In stock

Choose a purchase plan:
If you decide a subscription is not for you, it can be cancelled after 30 days.

Glucosamine sulfate and chondroitin sulfate are two components of joint cartilage and other types of structural tissue, making them important nutrients in those with joint pain. Both ingredients are commonly used for their ability to reduce pain and improve function in the joints of arthritis sufferers.

The main purpose of glucosamine and chondroitin is to provide structural support for joint cartilage. Chondroitin provides resistance against compression forces, while glucosamine provides support for both the cartilage and the synovial fluid surrounding the joints that helps cushion them and reduce friction. Therefore, these compounds are most often taken by those with osteoarthritis to reduce joint breakdown and pain.

Subjects supplementing with glucosamine and chondroitin have been able to reduce their use of non-steroidal anti-inflammatory drugs (NSAIDs), and although these natural supplements take longer to provide relief than NSAIDs, their beneficial effects have been shown to last longer.

AOR Advantage

AOR’s Glucosamine & Chondroitin provides two well researched nutrients in therapeutic dosages, providing natural and effective relief for joint pain in a shell-fish free formula.

 

NPN

80042966

Discussion

Glucosamine sulfate and chondroitin sulfate are components of the cartilage in joint tissue, supporting joint structure by aiding in the formation of connective tissue and protecting against the deterioration of cartilage from chronic joint diseases, while helping to relieve joint pain associated with osteoarthritis.

Guarantees

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish or shellfish.

Adult Dosage

Take three to four capsules daily with food, or as directed by a qualified health care practitioner. Allow a minimum of one month to see beneficial effects.

Cautions

Consult a health care practitioner prior to use if you are pregnant, breastfeeding or if symptoms worsen with ongoing supplementation. This product contains corn derived ingredients, do not use if you have an allergy.

Main Applications
  • Osteoarthritis
  • Sports injuries
  • Cartilage regeneration
Disclaimer

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Capsule

Non-medicinal Ingredients: Microcrystalline cellulose, sodium stearyl fumarate.

Capsule: hypromellose.

Relieves Symptoms of Osteoarthritis (OA)

Study #1:

In this 2018, systematic review and meta-analysis published in Clinical Rhumatology, the authors reviewed 18 articles written between 2003 and 2016  recent randomized controlled trials on glucosamine for knee OA to reveal up-to-date findings about this supplement and performed a meta-analysis of some of the outcomes to overcome the unsolved bias in each study.

This analysis found Glucosamine has the potential to alleviate knee OA pain. Further studies are needed to evaluate the effect of glucosamine on knee function and joint preservation, as well as to evaluate the combined effect with other components, such as chondroitin.

Ogata T, Ideno Y, Akai M, et al. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clin Rheumatol. 2018;37(9):2479-2487. doi:10.1007/s10067-018-4106-2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097075/

Study #2:

A study published in the American Journal of Sports Medicine in 2014 consisting of a systematic review of 13 randomized controlled trials evaluated the effectiveness of 12 different agents in preserving articular cartilage of the knee and delaying the progression of osteoarthritis.

Treatment with chondroitin sulfate showed a significant reduction in cartilage loss in three of four studies identified compared with placebo. Two of three trials identified for glucosamine also reported significant structural effects relative to placebo. Intra-articular hyaluronic acid was effective in lowering the rate of cartilage loss in only one of three studies identified versus placebo. Of the six studies identified for NSAIDs, vitamin E, and vitamin D, none showed any structural effect compared with placebo.

For patients with or at risk for osteoarthritis, the use of glucosamine and chondroitin sulfate may serve as a nonoperative means to protect joint cartilage and delay osteoarthritis progression. Hyaluronic acid injections showed variable efficacy, while NSAIDs and vitamins E and D showed no effect on osteoarthritis progression. The other agents evaluated had no evidence in the literature to support or refute their use for chondroprotection.

Gallagher B, Tjoumakaris FP, Harwood MI, Good RP, Ciccotti MG, Freedman KB. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med. 2015 Mar;43(3):734-44. doi: 10.1177/0363546514533777. Epub 2014 May 27. PMID: 24866892. https://pubmed.ncbi.nlm.nih.gov/24866892/

Study #3:

Pharmaceutical-grade chondroitin sulfate (CS) was repeatedly reported to reduce pain and improve function in patients with knee OA. This treatment was also shown to be cost-effective, compared to placebo, up to 24 months. However, controversies persist regarding the usefulness of CS for patients with knee OA, mainly due to inconsistent reports from various clinical trials. In this literature review, the authors summarized the main most recent findings on the efficacy and safety of CS in OA.

Based on the results of studies presenting a low risk of bias, the most recent meta-analysis shows that only the pharmaceutical-grade CS may be considered as an appropriate background treatment for the management of knee OA. Evidence from another recent meta-analysis, using data from full safety reports, confirms the good safety profile of CS in OA. This new evidence on efficacy and safety suggests that recommendations for the use of CS in patients with knee OA cannot be extrapolated to other low-grade preparations as generics, nutraceutical-grade or over-the-counter preparations.

Honvo G, Bruyère O, Reginster JY. Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. Aging Clin Exp Res. 2019;31(8):1163-1167. doi:10.1007/s40520-019-01253-z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661017/

Study #4:

A meta-analysis of randomized controlled trials published in Journal of Orthopaedics Surgery and Research in 2018 assessed the symptomatic effectiveness and safety of oral symptomatic slow-acting drugs (SYSADOAs) on the treatment of knee and/or hip osteoarthritis, such as chondroitin, glucosamine, and combination treatment with chondroitin plus glucosamine. Twenty-six articles describing 30 trials met the inclusion criteria and were included in the meta-analysis.

Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function. Glucosamine showed effect on stiffness outcome. Regarding on the limited number of combination therapy, further studies need to investigate the accurate effectiveness. This information accompanied with the tolerability and economic costs of included treatments would be conducive to making decisions for clinicians.

Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018;13(1):170. Published 2018 Jul 6. doi:10.1186/s13018-018-0871-5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035477/